Clinical laboratory
Healthcare issues related to clinical laboratories;
 
H.R. 4128/S. 2209, the Verifying Accurate Leading-edge IVCT Development (VALID) Act, provisions relating to FDA oversight of laboratory-developed tests;
 
Federal policy related to implementation of the Families First Coronavirus Response Act, Pub. L. 116-127, provisions relating to coverage of and funding for COVID-19 diagnostic tests;
 
Federal policy related to implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act, Pub. L. 116-136, provisions relating to coverage and reimbursement of COVID-19 diagnostic tests and Medicare reimbursement for clinical laboratory tests;

S. 610, the Protecting Medicare and American Farmers from Sequester Cuts Act, provisions relating to delays in data collection and rate changes pertinent to the Medicare Clinical Laboratory Fee Schedule, mitigation of the Medicare sequester and rate changes pertinent to the Medicare Physician Fee Schedule, and suspension of certain statutory pay-as-you-go requirements;
  
Federal policy relating to reform of Medicare reimbursement for clinical laboratory services under Section 216 of the Protecting Access to Medicare Act, Pub. L. 113-93; and
 
H.R. 6000, the Cures 2.0 Act, provisions relating to pandemic preparedness, improvements in clinical research processes, and advancement of genetic and genomic testing, 

S. 1605, the National Defense Authorization Act for Fiscal Year 2022, provisions relating to TRICARE coverage of preconception and prenatal carrier screening;
HCR - Health Issues
2 - HOUSE OF REPRESENTATIVES 1 - SENATE
KELLEY DRYE & WARREN LLP
3050 K STREET, NW, SUITE 400, WASHINGTON, DC, 20007, US
DANA SCHNEEBERGER WOOD SCOTT MCGEE MAGGIE CLARKE CROSSWY